SVP, Pathology & Diagnostic Medicine
Foundation Medicine Inc.
Julia A. Elvin, MD PhD is Senior Vice President, Pathology and Diagnostic Medicine at Foundation Medicine, Inc. where she leads a team of physicians who help people living with cancer find their best treatment path by performing and interpreting comprehensive genomic profiling of tumor tissue and blood. In her role as the Medical Director of the FMI CLIA laboratory in Cambridge, MA, she is also responsible for oversight of all areas of laboratory clinical operations of high complexity, next generation sequencing-based testing of specimens from oncology patients.
Dr. Elvin joined FMI in 2014 and has contributed to the development, validation, FDA-approval & launch of assays including FoundationOneCDx, FoundationOneLiquidCDx and FoundationFocusCDx -BRCA. Dr. Elvin’s research interests include the genomic underpinnings of a diverse array of tumor types with a particular focus on gynecologic malignancies, the application of tumor molecular profiling to diagnosis, prognosis, and therapy selection, and the impact of preanalytic specimen factors on testing.
Prior to joining FMI Dr. Elvin practiced diagnostic pathology, cytology and laboratory medicine for 8 years as the Director of Women’s Health Pathology in a regional reference pathology laboratory (Converge Diagnostic Services). Dr. Elvin’s particular interest in the molecular drivers of gynecologic tumors stems from her subspecialty pathology training and early bench research. She was a trainee in the MSTP program at Baylor College of Medicine in Houston, TX where she obtained her MD and PhD in Human and Molecular Genetics studying female reproductive system effects of TGF-beta family members using knockout mouse models. Her anatomic pathology training included an internship at the Baylor Affiliated Hospitals Pathology program, Anatomic Pathology residency and Women’s and Perinatal Pathology fellowship at Brigham and Women’s Hospital in Boston, MA where she also served as Chief Resident.